【摘要】 免疫疗法是近年血液肿瘤治疗领域的研究热点，随着基因工程及分子生物学技术的发展及对肿瘤发病机制认识的不断深入，嵌合抗原受体T细胞（chimeric antigen receptor T cell,CAR-T）疗法在临床中得到广泛应用。CAR-T细胞疗法治疗难治复发急性淋巴细胞白血病、难治侵袭性淋巴瘤、多发性骨髓瘤取得了令人振奋的疗效，极大改善了患者的预后，但仍有相当一部分患者存在对治疗无应答或在短期内复发以及接受治疗后发生不可耐受的细胞因子释放综合征等不良反应的问题；以嵌合抗原受体为基础的CAR-NK、CAR-M细胞的研究和减轻CAR-T治疗毒副作用及临床长期应答疗效的研究还存在许多挑战和机遇，任重而道远。本文就CAR-T细胞疗法在难治复发血液肿瘤中的应用做一评述，并对发展前景予以展望。更多还原

【Abstract】 Immunotherapy has emerged as a research hotspot in the field of hematological tumor treatment in recent years. With advancements in genetic engineering and molecular biology, and a deeper understanding of tumor pathogenesis, Chimeric Antigen Receptor T cell(CAR-T) therapy has found widespread application in clinical practice. CAR-T cell therapy has shown remarkable efficacy in treating refractory and relapsed acute lymphoblastic leukemia, refractory aggressive lymphoma, and multiple myeloma, greatly improving patient prognosis. Despite these wonderful clinical outcomes, there still exist many patients couldn’t get continuous remission or show no responses to CAR-T therapy. Additionally, cytokine release syndrome(CRS) is the most significant and life-threatening toxicity which needs more clinical experiences. The researches CAR-NK and CAR-M are new techniques based on the CAR-T cell treatment, but still needs more efforts to make car therapy safer and more efficient. All above may guide new challenges and important discoveries in immunotherapy of hematological malignancies.This article reviewed the application of CAR-T Cell therapy in the treatment of refractory and recurrent hematological tumors, and looked forward to its development prospects.更多还原